SCHEMBL6917360

SCHEMBL6917360

CC(C)(C)C(=O)OC[PH](=O)OC[C@H]1O[C@@H](n2cnc(C#N)n2)[C@H](O)[C@@H]1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ADORA1 P30542 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
EIF4E P06730 1/20 0.38
CYP3A4 P08684 1/20 0.38
TOP1 P11387 1/20 0.38
TSHR P16473 1/20 0.38
THPO P40225 1/20 0.38
PMP22 Q01453 1/20 0.38
PNP P00491 3/20 0.36
ATG7 O95352 7/20 0.34
ADORA3 P0DMS8 1/20 0.33
CCNT1 O60563 1/20 0.31
CCNK O75909 1/20 0.31
CDK7 P50613 1/20 0.31
CDK9 P50750 1/20 0.31
CCNH P51946 1/20 0.31
MNAT1 P51948 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914227 0.82 LMNA (0.39) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6917119 0.82 LMNA (0.42) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6914219 0.80 LMNA (0.40) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6917358 0.79 LMNA (0.39) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12151512 0.76 ADORA3 (0.44) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12150458 0.74 LMNA (0.45) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL9780402 0.73 ATG7 (0.58) ATG7
SCHEMBL9780439 0.73 LMNA (0.59) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL13320587 0.73 LMNA (0.59) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL13352081 0.73 LMNA (0.59) LMNASMN1; SMN2ADORA1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs BIOTA HOLDINGS LIMITED (AU) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs MTAP, ENTPD5, PNP LMNA 4394/4885SMN1; SMN2 2624/4885ADORA1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.